Clinical Trials Details

NRG-GY018 (Endometrial)

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Objective

The dMMR Cohort is closed.

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms